Longitudinal evaluation of markers of hemostasis in pregnancy

Bratislava Medical Journal

Volumn 115, Issue 3, 2014, Pages 140-144

  Hammerova, L ^a   Chabada, J ^a   Drobny, J ^a   Batorova, A ^a  

^a Faculty of Natural Sciences   (Slovakia)

Author keywords

hemostasis; hypercoagulable state; pregnancy; venous thromboembolism

Indexed keywords

BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN;

ARTICLE; FEMALE; GENETICS; HEMOSTASIS; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; POINT MUTATION; PREECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PROSPECTIVE STUDY; THIRD TRIMESTER PREGNANCY; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

FACTOR V; FEMALE; HEMOSTASIS; HUMANS; POINT MUTATION; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY OUTCOME; PREGNANCY TRIMESTER, THIRD; PROSPECTIVE STUDIES; THROMBOPHILIA; VENOUS THROMBOEMBOLISM;

EID: 84894619729     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: 10.4149/BLL_2014_030     Document Type: Article

References (36)

1. Nijkeuter M, Ginsberg JS, Huisman MV. Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy: a systematic review. J Thromb Haemost 2006; 4: 496-500.
2. Bourjeily G, Paidas M, Khalil H, Rosene-Montella K, Rodger M. Pulmonary embolism during pregnancy. Lancet 2010; 375 (9713): 500-512.
3. Martinelli I, Bucciarelli P, Mannucci PM. Thrombotic risk factors: Basic pathophysiology. Crit Care Med 2010; 38 (2): 3-9.
4. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous Thromboembolism, Thrombophilia, Antithrombotic Therapy, and Pregnancy American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 844-886.
5. Trigg DE et al. Hormonal Infl uences on Hemostasis in Women. Semin Thromb Hemost 2011; 37 (1): 77-86.
6. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799.
7. Tikkanen M, Nuutila M, Hiilesmaa V, Paavonen J, Ylikorkala O. Clinical presentation and risk factors of placental abruption. Acta Obstet Gynecol Scand 2006; 85(6): 700-705.
8. Cox P, Marton T. Pathological assessment of intrauterine growth restriction. Best Pract Res Clin Obstet Gynaecol 2009; 23 (6): 751-764.
9. Burton GJ, Watson AL, Hempstock J, Skepper JN, Jauniaux E. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. J Clin Endocrinol Metab 2002; 87: 2954-2959.
10. Burrows RF. Platelet disorders in pregnancy. Curr Opin Obstet Gynecol 2001; 13 (2): 115-119.
11. Sainio S, Kekomäki R, Riikonen S, Teramo K. Maternal thrombocytopenia at term-a population-based study. Acta Obstet Gynecol Scand 2000; 79: 744-749.
12. Bremme K. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16 (2): 153-168.
13. O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17: 385-396.
14. Dempfle CE. What role does the measurement of fibrinogen and its derivatives have in the diagnosis of disseminated intravascular coagulation? Blood Rev 2002; 16 (1): S23-S28.
15. Dempfle CE, Wurst M, Smolinski M, Lorenz S, Olenik D et al. Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score. Thromb Haemost 2004; 91: 815-818.
16. Dempfle CE. Validation, calibration and specificity of quantitative Ddimer assay. Sem Vasc Med 2005; 5: 315-320.
17. Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity. Protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 1166-1170.
18. Asakura H, Obshita T, Suzukis S, Araki T. Correlation between grade III placenta and plasma antithrombin III activity in full term pregnancy. Gynecol Obstet Invest 2001; 52: 47-50.
19. Kher A, Bauersachs R, Nielsen JD. The management of thrombosis in pregnancy: Role of low-molecular-weight heparin. Thromb Haemost 2007; 97 (4): 505-513.
20. Redman CWG, Sargent IL. Preeclampsia, the Placenta and the Maternal Systematic Infl ammatory Response-A Review. Placenta 2003; 24 (Suppl A): S21-S27.
21. Many A, Schreiber L, Rosner S, Lessing JB, Eldor A, Kupferminc MJ. Pathologic features of the placenta in women with severe pregnancy complications and thrombophilia. Obstet Gynecol 2001; 98: 1041-1044.
22. Triplet DA, Harris EN. Antiphospholipid antibodies and reproduction. Am J Reprod Immunol 1989; 21: 123-131.
23. Sanson BJ, Friedrich PW, Simioni P. The risk of abortion and stillbirth in antithrombin-, protein C-, and protein S-deficient women. Thromb Haemost 1996; 75: 387-388.
24. Sullivan EA, Silver RM, LaCoursiere DY, Porter TF, Branch DW. Recurrent fetal aneuploidy and recurrent miscarriage. Obstet Gynecol 2004; 104: 784-788.
25. Ray E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361: 901-908.
26. Dizon-Townson D, Miller C, Sibai B, Spong CY, Thom E, Wendel Jr G. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005; 106: 517-524.
27. Clark P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO (H) blood groups on hemorrhagic an thrombotic pregnancy outcomes. Br J Haematol 2007; 140: 236-240.
28. The GOPEC Consortium. Disentangling fetal and maternal susceptibility for pre-eclampsia: A British multicenter candidate--gene study. Am J Hum Genet 2005; 77: 127-131.
29. De Groot CJM, Bloemenkamp KWM, Duvenkot EJ, Helmerhorst FM, Bertina RM, Vander Meer F et al. Preeclampsia and genetic risk factors for thrombosis: A case--control study. Am J Obstet Gynecol 1999; 181: 975-980.
30. Kim YJ, Williamson RA, Murray JC, Andrews J, Pietscher JJ et al. Genetic susceptibility to preeclampsia: Roles of cytosine-to-thymine substitution at nucleotide 677 of the gene for methylenetetrahydrofolate reductase, 68-base pair insertion at nucleotide 844 of the gene for cystathionine β-synthase, and factor V Leiden mutation. Am J Obstet Gynecol 2001; 184: 1211-1217.
31. Mello G, Parretti E, Marozio L, Pizzi C, Lojacono A, Frusca T et al. Thrombophilia is significantly associated with severe preeclampsia. Hypertension 2005; 46: 1270-1274.
32. O'Shaughnessy KM, Fu B, Ferraro F, Lewis I, Downing S, Morris NH. Factor V Leiden and thermolabile methylenetetrahydrofolate reductase gene variants in an East Anglian preeclampsia cohort. Hypertension 1999; 33: 1338-1341.
33. Lindquist P, Dahlbäck B, Maršál K. Thrombotic risk during pregnancy: A population study. Obstet Gynecol 1999; 94: 595-599.
34. Jääskeläinen E, Tiovonen S, Romppanen EL, Helisalmi S, Keski-Nisula L, Punnonen K, Heinonen S. M385T polymorphism in the factor V gene, but not Leiden mutation, is associated with placental abruption in Finnish women. Placenta 2004; 25: 730-734.
35. Procházka M, Happach C, Maršál K, Dahlbäck B, Lindquist PG. Factor V Leiden in pregnancies complicated by placental abruption. BJOG 2003; 110: 462-466.
36. Procházka M, Lubuškỳ M, Slavík L, Hrachovec P, Zielina P, Kudela M, Lindquist PG. Frequency of selected thrombophilias in women with placental abruption. Aust N Z J Obstet Gynaecol 2007; 47 (4): 297-301.